Selpercatinib before radioactive iodine for RET-positive thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 25 years old.
- You have a type of thyroid cancer called differentiated thyroid cancer that has spread to your neck or lungs, and you haven't had any other cancer medicines yet (except radioactive iodine).
- A test shows that your tumor has a change in the RET gene (a RET fusion or mutation).
- You are in generally good health, with your organs (like bone marrow, kidneys, and liver) working well enough to handle the study drug.
- You are not pregnant or breastfeeding, and you agree to use birth control during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
This trial tests an oral drug called selpercatinib for people with certain cancers that have changes in the RET gene. It is for patients in India with advanced non-small cell lung cancer, medullary thyroid cancer, or other solid tumors that have not responded well to previous treatments.
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.